@GKochharMD Hi sir I’m a crohns patient from India

@GKochharMD Hi sir I’m a crohns patient from India, bangalore. Following your tweets. Happy that I found u n others.

@piersmorgan Try exercise in water even if tired i

@piersmorgan Try exercise in water even if tired it gets your muscles working. I have severe fatigue especially whe… https://t.co/CWAEdga8Z6

Signs that I’m dealing with a pesky #Crohns infection: repeatedly refreshing my @umichmedicine app for test results… https://t.co/hs1foOD7v5

@jcoff316 @strokeogenious1 @RBReich Uh yeah so vaccines are actually a tiny % of pharma products in terms of volume… https://t.co/PTDJS9LmSn

Approval Of First Interchangeable Biosimilar, Semglee, Is Sign Of An Improving U.S. Biosimilars Market, Despite Cha… https://t.co/qKcn7BQf5G

“Approval Of First Interchangeable Biosimilar, Semglee, Is Sign Of An Improving U.S. Biosimilars Market, Despite Ch… https://t.co/z3fjcg5b0o

Approval Of First Interchangeable Biosimilar, Semglee, Is Sign Of An Improving U.S. Biosimilars Market, Despite Cha… https://t.co/8FAHiAOj1O

Approval Of First Interchangeable Biosimilar, Semglee, Is Sign Of An Improving U.S. Biosimilars Market, Despite Cha… https://t.co/IpnCOxBJUA

Approval Of First Interchangeable Biosimilar, Semglee, Is Sign Of An Improving U.S. Biosimilars Market, Despite Cha… https://t.co/CerLVVOEnK

Approval Of First Interchangeable Biosimilar, Semglee, Is Sign Of An Improving U.S. Biosimilars Market, Despite Cha… https://t.co/ga7qsVUILG